Probing the dynamics of O-GlcNAc glycosylation in the brain using quantitative proteomics. Nat. Chem. Biol. 3, 339-48 (2007). The addition of the monosaccharide β-N-acetyl-D-glucosamine to proteins (O-GlcNAc glycosylation) is an intracellular, post-translational modification that shares features with phosphorylation. Here, we demonstrate a new strategy for monitoring the dynamics of O-GlcNAc glycosylation using quantitative mass spectrometry-based proteomics. Our method, termed QUIC-tag, combines selective, chemoenzymatic tagging of O-GlcNAc proteins with an efficient isotopic labeling strategy. A key advantage of the approach is that it can be applied to postmitotic cells such as neurons after in vivo stimulation. Using the method, we detect changes in O-GlcNAc glycosylation on several proteins involved in the regulation of transcription and mRNA translocation. We also provide the first evidence that O-GlcNAc glycosylation is dynamically modulated by excitatory stimulation of the brain in vivo. Finally, we employ electron transfer dissociation (ETD) mass spectrometry to identify exact sites of O-GlcNAc modification. Together, our studies suggest that O-GlcNAc glycosylation occurs reversibly in neurons and, akin to phosphorylation, may play important roles in mediating the communication between neurons.
O-GlcNAc dynamics on specific proteins. In this approach, which we have termed Quantitative Isotopic and Chemoenzymatic Tagging (QUIC-Tag), lysates from two cellular states (e.g., stimulated vs. unstimulated, diseased vs. normal) were chemoenzymatically labeled and proteolytically digested (Scheme 1). A modified dimethyl labeling strategy 2 incorporated stable isotopes into peptide N-terminal amines and ε-amino groups of lysine residues by reductive amination for subsequent MS quantification.
Treatment with either formaldehyde/NaCNBH 3 or deuterated formaldehyde/NaCNBD 3 created mass differences of 6 x n between the peptides from the two cell populations, where n is the number of primary amine functionalities in the peptide. This allowed for complete resolution of isotopic envelopes even at higher charge states (i.e., +4) during MS analysis. Following isotopic labeling, we combined 
Quantification of Known O-GlcNAc Peptides from Complex Mixtures
Nelly Khidekel first evaluated the effectiveness of the dimethyl labeling strategy using the model protein α-casein. α-casein was digested with trypsin, and the resulting peptides were reacted with formaldehyde and NaCNBH 3 at pH values ranging from 5-8.
Liquid chromatography-mass spectrometry (LC-MS) analysis of the labeled peptides indicated that reductive amination proceeded quantitatively for both lysine and Nterminal primary amines in less than 10 min at pH 7 (data not shown). In contrast to previous studies 2 , we observed that higher pH values were necessary to achieve complete labeling of basic lysine residues.
Having established the optimal conditions for dimethyl labeling, Nelly investigated our ability to capture and quantify known O-GlcNAc peptides 3, 4 from complex mixtures. Known amounts of the proteins α-crystallin (ca. 300 pmol) and OGT (ca. 10 pmol) were added to two samples of rat brain lysate. We chose to examine αcrystallin because of its low stoichiometry of glycosylation (<10%) and because it has represented a formidable challenge for detection by several methods 1, 5 . The samples were chemoenzymatically labeled, proteolytically digested, isotopically labeled and combined as described in Scheme 1. Following avidin capture of the O-GlcNAc peptides, Scott Ficarro performed relative quantification of glycosylated peptide pairs using an orbitrap mass spectrometer 6 , which provided accurate mass (<20 ppm) and high resolution (100,000 at m/z 400) ion measurements. Precursor peptide cations that exhibited the signature loss of the labile ketogalactose-biotin and GlcNAc-ketogalactosebiotin groups during MS/MS were subjected to further fragmentation via MS 4 .
In these experiments, Nelly and Scott reproducibly captured and quantified 3 αcrystallin peptides that encompass all of the known glycosylation sites on both the A and B forms of α-crystallin 3, 7 . Additionally, Nelly captured 8 OGT peptides representing all 1 . The deuterated and non-deuterated peptides generally co-eluted during reversed-phase chromatography ( Fig. 1a) , minimizing the isotope resolution effects during LC previously reported to interfere with deuterium-labeled peptides 2, 8 . To quantify the relative amounts of each peptide, Nelly compared the ratio of signal intensities from the heavy to the light forms, across the entire chromatographic profile of each peptide ( Fig. 1b) 
Probing the Reversibility of O-GlcNAc Glycosylation in Neurons using QUIC-Tag
We next applied the approach to study the reversibility of the O-GlcNAc modification in neurons. Although studies have suggested that O-GlcNAc levels can be modulated in various cell types 11, 12 , the neuronal proteins that undergo reversible glycosylation are largely unknown. Nelly treated cultured cortical neurons from embryonic day-18 rats with the OGA inhibitor PUGNAc (O-(2-acetamido-2-deoxy-Dglucopyranosylidene)amino-N-phenylcarbamate) 13 for 12 h. PUGNAc has been shown to ketogalactose-biotin and GlcNAc-ketogalactose-biotin signature fragmentation patterns.
To obtain the relative change in glycosylation on specific peptides, we corrected the heavy:light ratios using a normalization factor derived from the linear regression of the α-crystallin and OGT standard ratios within each sample. Analysis of standard peptides suggests that we could detect 1.15-fold changes in the nuclear sample and 1.70-fold changes in the cytoplasmic sample with 95% confidence (see Methods for statistical analysis). The peptide standards formed a normal distribution around the mean standard ratio as measured by the D'Agostino-Pearson omnibus test, suggesting that ratios greater than 2 standard deviations (σ) of the mean ratio are likely significant.
Using these criteria, 22 peptides from the nuclear sample and 11 peptides from the corresponding cytoplasmic sample showed an increase in O-GlcNAc glycosylation upon PUGNAc stimulation ( Fig. 2b) . Interestingly, we found that the presence of PUGNAc did not result in increased O-GlcNAc glycosylation on all proteins. For example, in the same nuclear sample, 4 O-GlcNAc peptides showed no measurable change in glycosylation, whereas in the cytoplasmic sample 16 peptides showed no measurable change ( Fig. 2c) . We also observed decreases in glycosylation on 5 nuclear and 4
cytoplasmic O-GlcNAc peptides ( Fig. 2d) . These site-dependent differences suggest differential regulation of the modification in cells, with some proteins being more susceptible to reversible cycling than others.
Identification of Proteins Subject to Reversible Glycosylation in Neurons
To identify the neuronal proteins undergoing reversible glycosylation, Scott targeted a portion of the O-GlcNAc peptides for sequencing by MS 4 analysis. A representative ESI-MS spectrum of an O-GlcNAc peptide whose glycosylation state was elevated upon PUGNAc treatment is shown (Fig. 3a) . The CAD MS 2 spectrum of the deuterated, triply charged peptide (m/z = 862.389) displays a characteristic loss of a ketogalactose-biotin moiety (m/z = 1208.4) and GlcNAc-ketogalactose-biotin moiety (m/z = 1005.3) ( Fig. 3b) . MS 4 analysis generated a series of b-and y-type product ions and internal cleavages that enabled definitive sequencing of the peptide (Fig. 3c,d) . Database searching identified the peptide as belonging to the protein translation elongation initiation factor 4G (eIF4G).
To sequence O-GlcNAc-containing peptides and locate the exact sites of glycosylation, Nelly and Danielle Swaney also employed a recently reported fragmentation method, electron transfer dissociation (ETD) 14, 15 . ETD utilizes small molecule radical anions to deliver electrons to isolated peptide precursor cations. After receiving the electron, the odd-electron peptide cation undergoes backbone fragmentation with minimal cleavage of amino acid side chains. This results in the production of sequence-specific c-and z-type product ions without the loss of labile post-translational modification -dissociation pathways that can dominate CAD spectra. As ETD has been successfully used to elucidate exact sites of phosphorylation 14 and N-glycosylation 16 , we envisioned that it might be a powerful approach for mapping O-GlcNAc glycosylation sites. A representative ETD tandem mass spectrum of an O-GlcNAc-modified peptide whose glycosylation level was increased in the PUGNAc-treated sample is shown ( Fig.   4a ). ETD provided near complete sequence coverage for this peptide (Fig. 4b) , belonging to the transcriptional repressor p66β. Importantly, the O-GlcNAc linkage was preserved during ETD fragmentation, and we observed the added mass corresponding to the tagged O-GlcNAc moiety on the c-type product ion series. The tagged O-GlcNAc-modified c3 ion narrowed the O-GlcNAc glycosylation site to the N-terminal Ser-584 or Ser-586 of this peptide ( Fig. 4c) . ETD was highly effective for the fragmentation of lower m/z
GlcNAc-ketogalactose-biotin peptide precursor cations (e.g., < ~800), but was less effective for precursors above this m/z value. Recent work suggests supplemental collisional activation of the electron transfer product species can help counter this problem 17 .
Using a combination of CAD and ETD, Scott and Danielle sequenced 7 of the O-GlcNAc peptides that undergo significant increases in glycosylation upon PUGNAc treatment ( Table 2 ). In addition, Danielle identified another peptide by ETD that was not observed in the orbitrap MS analysis and thus could not be quantified. Among the O-GlcNAc proteins subject to reversible glycosylation are the transcriptional coactivator SRC-1 and the zinc finger RNA-binding protein, which we had previously identified as O-GlcNAc glycosylated 3 . Here, we extend those findings by identifying the exact site of glycosylation on both proteins using ETD and by showing that glycosylation at those sites occurs reversibly in neurons. We also identified an O-GlcNAc peptide on the RNAbinding protein nucleoporin 153, which had been previously shown to be O-GlcNAc glycosylated 18 , but whose glycosylated peptides were unknown. In addition to these, we identified reversible sites of modification on several new proteins, including the transcriptional repressor p66β, translation factor eIF4G, and the neuron-specific transcriptional repressor BHC80. Finally, we found that the enzyme OGA is O-GlcNAc glycosylated in neurons, which is consistent with the ability of OGT to glycosylate OGA in vitro 19 . Inhibition of OGA using PUGNAc led to a robust increase in OGA 
O-GlcNAc Glycosylation Is Regulated by Excitatory Stimulation In Vivo
Having demonstrated the reversibility of the O-GlcNAc modification in neurons, we next investigated whether O-GlcNAc glycosylation is induced in vivo by neuronal stimulation. Jessica Rexach and I intraperitoneally injected rats with kainic acid, a kainate-type glutamate receptor agonist that produces a robust excitatory stimulus of the brain. Kainic acid has been used to study excitatory pathways that induce gene expression and synaptic plasticity 21 and to invoke seizures as a well-characterized model for temporal lobe epilepsy 22 . We dissected the cerebral cortices of kainic acid-treated rats at distinct behavioral time points: 2.5 h post-injection at peak of seizure, 6 h postinjection when animals had resumed some normal resting behavior, and 10 h postinjection when animals showed nearly identical behavior to saline-injected controls.
Global changes in O-GlcNAc levels were measured by immunoblotting the cortical cell lysate with an anti-O-GlcNAc antibody. I found that O-GlcNAc levels on several proteins were elevated at 6 h post-injection and returned to basal levels by 10 h postinjection ( Fig. 6a) .
To identify proteins undergoing changes in O-GlcNAc glycosylation in response to kainic acid, Nelly applied our quantitative proteomics strategy to cortical lysates Specifically, the changes for these peptides were greater than 2 σ over the mean of the 1:1 standard peptides for multiple experiments. Using CAD tandem mass spectrometry, Scott successfully identified 4 of these proteins as eIF4G, the transcription factor early growth response-1 (EGR-1), the trafficking protein Golgi reassembly stacking protein 2 (GRASP55), and the HIV-1 Rev-binding protein (Hrb; Fig. 6b and Table 3 ).
Interestingly, the same peptide of eIF4G that undergoes reversible glycosylation upon
PUGNAc treatment also undergoes a change in glycosylation in response to kainic acid.
Scott also sequenced 3 O-GlcNAc peptides that did not undergo reproducible changes in glycosylation ( Table 3 ).
I confirmed that the observed increases in O-GlcNAc glycosylation were not due to enhanced protein expression by immunoblotting cortical lysates of kainic acid-treated or control PBS-treated rats with available antibodies against the proteins of interest.
Consistent with previous reports that EGR-1 expression is upregulated approximately twofold in the cerebral cortex following kainic acid administration 23 , I found that EGR-1 expression was elevated 1.8 ± 0.2-fold at 6 h post-injection ( Fig. 7) . Given that O- Similarly, the change in eIF4G expression was modest (1.5 ± 0.1) relative to the change in its O-GlcNAc level (4.9 ± 0.7), and GRASP55 underwent a decrease in protein expression level with kainic acid treatment (0.61 ± 0.09). To our knowledge, these data represent the first demonstration that extracellular stimuli beyond glucose concentrations in the brain contribute to the dynamics of O-GlcNAc glycosylation.
Table 3 Identification and quantification of changes in O-GlcNAc glycosylation induced by kainic acid

Expanding the O-GlcNAc Proteome of the Brain
In addition to obtaining quantitative information on the dynamics of O-GlcNAc glycosylation, we also identified 20 O-GlcNAc peptides corresponding to 6 new and 12
previously characterized O-GlcNAc proteins from the brain ( One of the proteins whose glycosylation level is significantly increased by PUGNAc treatment is the transcriptional repressor p66β. p66β interacts with histone tails and mediates transcriptional repression by the methyl-CpG-binding domain protein MBD2 31 . Our observation that p66β is reversibly O-GlcNAc glycosylated reinforces growing evidence that O-GlcNAc plays an important role in the regulation of gene expression 3, 4, 18, 25, 32, 33 . As p66β appears to be sumoylated in vivo in a manner that affects its repression potential 34 , our results also highlight a growing network of posttranslational modifications that may be fundamental for the regulation of transcription, and it provides a new target with which to study this process.
We also identified changes in glycosylation on several proteins involved in the transport and translocation of mRNA. Such processes are of particular interest in neurons, where regulated transport of mRNA from the cell body to dendrites and dendritic translation of mRNA are involved in changes in synaptic strength that give rise to synaptic plasticity 35 . In particular, we found reversible O-GlcNAc glycosylation on the zinc finger RNA-binding protein, which is associated with staufen2 granules in neurons 36 and may be important in the early stages of RNA translocation from the nucleus to the dendrites. We also observed enhanced glycosylation of a peptide from the C-terminal domain of nucleoporin 153, a protein necessary for docking and trafficking of mRNA 37 .
In addition to studying the reversibility of O-GlcNAc in neurons, we demonstrated for the first time that O-GlcNAc glycosylation is regulated in vivo by robust excitatory stimulation. For example, we found that EGR-1, an immediate early gene and transcription factor important for long-term memory formation 38 and cell survival 39 , undergoes a tenfold increase in glycosylation upon kainic acid stimulation. As the site of glycosylation resides in the N-terminal transactivation domain of EGR-1, one possibility is that O-GlcNAc may influence the transactivation potential of EGR-1 and modulate the expression of genes such as the synapsins and proteasome components 40 , which play critical roles in synaptic plasticity.
We also observed an increase in O-GlcNAc glycosylation on the translation factor eIF4G upon kainic acid stimulation. As kainic acid treatment induces excitoxicity in addition to synaptic potentiation 41 and suppressed translation is a known marker for neuronal excitoxicity 42 , the potential regulation of eIF4G by O-GlcNAc glycosylation may represent a stress-induced response. It will be important to examine whether other cellular stresses induce glycosylation of eIF4G and other proteins to modulate translation and neuronal survival. Consistent with this possibility, other components of the translational machinery have been shown to be O-GlcNAc modified, such as p67, which binds to the eukaryotic initiation factor 2α (eIF2α) in its glycosylated form and promotes protein synthesis by preventing inhibitory phosphorylation of eIF2α 43 .
The ability of O-GlcNAc to respond to specific extracellular stimuli suggests a potential role for the modification in mediating neuronal communication. This notion is supported by the identification of a growing number of O-GlcNAc glycosylated proteins involved in neuronal signaling and synaptic plasticity 3, 30 . In the present study, we further expand the O-GlcNAc proteome of the brain to include proteins involved in synaptic vesicle trafficking, including Rab3 GEP, a protein involved in neurotransmitter release, and phosphatidylinositol clathrin protein, which mediates synaptic vesicle endocytosis.
In keeping with recent work by Vosseller and colleagues 30 , we find that the presynaptic protein bassoon, which is necessary for the creation of stable synapses and proper neuronal communication, is O-GlcNAc modified. We also identify O-GlcNAc glycosylation on signal transduction proteins such as the kinase AAK1, which is involved in clathrin-mediated synaptic vesicle endocytosis, and the synaptic Ras GTPase activating protein SynGAP, which plays a critical role in AMPA (alpha-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid) receptor trafficking and synapse formation.
Finally, our work highlights the emergent interplay between O-GlcNAc glycosylation and phosphorylation. For example, we identified a glycosylated peptide on bassoon that is likewise phosphorylated in vivo 44 . Moreover, the axonal guidance protein CRMP-2 is phosphorylated at two residues within the glycopeptide identified in our studies 45 . Interestingly, when hyperphosphorylated within the residues of this peptide,
CRMP-2 appears as a component of the neurofibrillary tangles associated with
Alzheimer's disease (AD). This is reminiscent of the microtubule-associated protein tau, which is also O-GlcNAc glycosylated but exists in hyperphosphorylated form in the AD brain 46 . Deciphering the mechanisms that regulate the interplay of glycosylation and phosphorylation for these and other proteins may have important ramifications for the study of neuronal signaling and neurodegenerative disorders.
In summary, we demonstrate a new quantitative proteomics strategy for studying the dynamics of O-GlcNAc glycosylation. Our findings reveal that the O-GlcNAc modification is reversible and dynamically regulated in neurons, and is found on many proteins essential for synaptic function. These observations, along with the discovery that excitatory stimulation can induce O-GlcNAc glycosylation in the brain, suggest that O-GlcNAc may represent an important post-translational modification for the regulation of neuronal communication. We envision that further application of this methodology will significantly advance our understanding of the regulation of O-GlcNAc glycosylation in the nervous system.
Methods
PUGNAc treatment of cortical cultures. Cortical neuronal cultures were prepared from embryonic day 18 or 19 Sprague Dawley rats as described 47 . Cells (8-12 x 10 6 ) were plated on 100-mm culture dishes coated with a 0.1 mg ml -1 sterile-filtered, aqueous solution of poly-DL-lysine (Sigma). Cells were maintained for 4 days at 5% CO 2 /37 ºC.
The media was replaced on the second day and immediately prior to PUGNAc treatment.
PUGNAc (Toronto Research Chemicals) was added to the cells at a final concentration of 100 µM (10 mM aqueous stock, sterile-filtered). After 12 h of incubation, the cells were scraped off the plates and pelleted. The media was removed by aspiration, and the cell pellet was washed with 1 ml of HEPES-buffered saline and lysed as described below.
Basal neurons were treated identically, except that a water control was used instead of PUGNAc. Chemoenzymatic labeling was performed on neuronal lysates as described above. After reaction with the aminooxy biotin derivative, proteins were dialyzed (1 x 10 h, 2 x 3 h) into 7 M urea, 10 mM HEPES, pH 7.5 at room temperature followed by 10 mM HEPES pH 7.5, 100 mM NaCl, 0.2% Triton-X 100 (2 x 2 h, 1 x 10 h) at 4 °C. Fresh PMSF (1 mM) was added at each stage of dialysis. Proteins were captured on streptavidin beads as previously described 4 and probed by immunoblotting.
Kainic acid administration. Male Long
Western blotting. Lysates were resolved by SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted as described previously 4 . Total O-GlcNAc levels were monitored using the anti-O-GlcNAc antibody CTD110.6 (Covance, 1:5000). The following primary antibodies were also used: EGR-1 (Upstate Biotechnology, 1:1000), GRASP-55 (BD Transduction Laboratories, 1:1000), eIF4G (Santa Cruz, 1:100), OGA (a kind gift from Prof. Sidney Whiteheart, University of Kentucky, 1:1000), p66β (Upstate, 1:500), and SRC-1 (Santa Cruz, 1:100). After incubation with the secondary antibodies IRDye 800 goat anti-rabbit (Rockland Immunochemicals) or Alexa Fluor 680 goat antimouse (Molecular Probes), proteins were visualized and quantified using the Odyssey infrared imaging system (LI-COR Biosciences). To quantify differences in O-GlcNAc levels, we measured the relative intensities of the input bands (lysate prior to streptavidin capture) and eluent bands (lysate after streptavidin capture) using Odyssey imaging software (Version 2.1). For each sample, we normalized the eluent signals to the input signals, and the resulting values from control reactions lacking GalT were subtracted from those values obtained from reactions containing GalT to correct for any nonspecific background.
Statistical analysis.
Quantification was conducted by generating single ion chromatograms from the orbitrap MS scans for candidate O-GlcNAc peptides. Peak areas of isotopic clusters were derived using Xcalibur 1.4 software. Mean values, standard deviations and confidence intervals were calculated using the program Excel on log-transformed ratios and reported in the original scale as previously described 2,3 . We used the geometric standard deviation (g.s.d.) to calculate maximum absolute standard deviations. Standard peptide ratios were tested for goodness of fit to the log-normal distribution via the D'Agostino-Pearson omnibus test and were used to determine the confidence with which changes in experimental peptides could be detected.
